Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil

Abstract Background Invasive cervical cancer is the second most common malignant tumor affecting Brazilian women. Knowledge on Human Papillomavirus (HPV) genotypes in invasive cervical cancer cases is crucial to guide the introduction and further evaluate the impact of new preventive strategies based on HPV. We aimed to provide updated comprehensive data about the HPV types’ distribution in patients with invasive cervical cancer. Methods Fresh tumor tissue samples of histologically confirmed invasive cervical cancer were collected from 175 women attending two cancer reference hospitals from São Paulo State: ICESP and Hospital de Câncer de Barretos. HPV detection and genotyping were performed by the Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, Pleasanton,USA). Results 170 out of 172 valid samples (99%) were HPV DNA positive. The most frequent types were HPV16 (77.6%), HPV18 (12.3%), HPV31 (8.8%), HPV33 (7.1%) and HPV35 (5.9%). Most infections (75%) were caused by individual HPV types. Women with adenocarcinoma were not younger than those with squamous cell carcinoma, as well, as women infected with HPV33 were older than those infected by other HPV types. Some differences between results obtained in the two hospitals were observed: higher overall prevalence of HPV16, absence of single infection by HPV31 and HPV45 was verified in HC-Barretos in comparison to ICESP patients. Conclusions To our knowledge, this is one of the largest studies made with fresh tumor tissues of invasive cervical cancer cases in Brazil. This study depicted a distinct HPV genotype distribution between two centers that may reflect the local epidemiology of HPV transmission among these populations. Due to the impact of these findings on cervical cancer preventive strategies, extension of this investigation to routine screening populations is warranted.

We thank Luciana Silva Aguiar and Cristiane de Campos Centrone for help in the patients’ selection and sample transportation, Coordenadoria de Estudos Clínicos do Núcleo de Apoio ao Pesquisador, Centro de Pesquisa em Oncologia Molecular, Comitê de Regulamentação e Manipulação de Materiais Biológicos and Gynecologic Oncology Department from Hospital de Câncer de Barretos – Fundação Pio XII. We also want to thank the Gynecologic Oncology Department from ICESP.

We thank Luciana Silva Aguiar and Cristiane de Campos Centrone for help in the patients’ selection and sample transportation, Coordenadoria de Estudos Clínicos do Núcleo de Apoio ao Pesquisador, Centro de Pesquisa em Oncologia Molecular, Comitê de Regulamentação e Manipulação de Materiais Biológicos and Gynecologic Oncology Department from Hospital de Câncer de Barretos – Fundação Pio XII. We also want to thank the Gynecologic Oncology Department from ICESP.